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Abstract 
24,25(OH)2D is the product of 25(OH)D catabolism by CYP24A1.The 
measurement of serum 24,25(OH)2D concentration may serve as an indicator of 
vitamin D catabolic status and the relative ratio with 25(OH)D can be used to 
identify patients with inactivating mutations in CYP24A1. We describe a LC-
MS/MS method to determine: 1) the relationships between serum 24,25(OH)2D 
and  25(OH)D; 2) serum reference intervals in healthy individuals; 3) the 
diagnostic accuracy of 24,25(OH)2D measurement as an indicator for vitamin D 
status; 4) 24,25(OH)2D cut-off value for clinically significant change between 
inadequate and sufficient 25(OH)D status. Serum samples of healthy participants 
(n=1996) from Army recruits and patients (n=294) were analysed. The LC-
MS/MS assay satisfied industry standards for method validation. We found a 
positive, concentration-dependent relationship between serum 24,25(OH)2D and 
25(OH)2D concentrations. The 25(OH)D:24,25(OH)2D ratio was significantly 
higher (p<0.001) at 25(OH)D <50 nmol/L. The reference interval for 
25(OH)D:24,25(OH)2D ratio in healthy subjects was 7-23. Measurement of serum 
24,25(OH)2D can be used as predictor of vitamin D status, a concentration of 
>4.2 nmol/L was identified as a diagnostic cut-off for 25(OH)D replete status. 
One patient sample with an elevated 25(OH)D:24,25(OH)2D ratio of 32 and 
hypercalcaemia who on genetic testing confirmed to have a biallelic mutation of 
CYP24A1. Our study demonstrated the feasibility of a combined 24,25(OH)2D 
and 25(OH)D assessment profile. Our established cut-off value for 24,25(OH)2D 
and ratio reference ranges can be useful to clinicians in the investigation of 
patients with an impaired calcium/phosphate metabolism and may point towards 
the existence of CYP24A1 gene abnormalities. 
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1.0 Introduction 
The vitamin D endocrine system plays a major role in human biological 
functions. The vitamin D pathway produces a large number of metabolites 
including 25-hydroxyvitamin D (25(OH)D), and 1,25-dihydroxyvitamin D 
(1,25(OH)D). Each vitamin D metabolites exists in two major forms: 
cholecalciferol (D3) is derived from sunlight (UVB) exposure on the skin and meat 
products; and ergocalciferol (D2) is derived from dietary plant sources. The 
synthesis of the metabolites are controlled by 25-hydroxylase in the liver and 1-
hydroxylase in the kidney. Severe deficiency of serum 25(OH)D results in 
decreased production of 1,25(OH)2D which is strongly associated with bone and 
neuromuscular diseases[1]. Epidemiological studies have shown an inverse 
relationship between serum 25(OH)D concentrations with a wide spectrum of 
disease states, including cardiovascular, cancer, diabetes, immunological and 
psychiatric disorders[2-8]. However, evidence from vitamin D intervention trials 
supporting beneficial effects of vitamin D supplementation on disease outcome 
are largely inconclusive[9-12]. The contradictory evidence indicates that the 
catabolism of 25(OH)D is a multistep process. Recent attention has centred on 
an alternative pathway of 25(OH)D metabolism driven by 24-hydroxylase 
producing 24,25-dihydroxyvitamin D (24,25(OH)2D). Studies have found limited 
biological activity of 24,25(OH)2D in humans, and similarly the metabolite 
1,24,25-trihydroxyvitamin D (1,24,25(OH)3D) which was considered to be an 
inactive excretory product of the vitamin D pathway[13]. The revival of interest in 
24,25(OH)2D is partly as a result of altered vitamin D catabolism discovered in 
patients with chronic kidney disease (CKD)[14], where impaired renal production 
of 1,25(OH)2D was found to be associated with decreased CYP24A1 
(cytochrome P450, family 24, subfamily A, polypeptide 1) activity. The CYP24A1 
gene is expressed in most tissues in the body[15, 16], it encodes the 24-
hydroxylase enzyme that catalyses the conversion of 25(OH)D and 1,25(OH)2D 
into 24-hydroxylated products[13]. The transcription of CYP24A1 gene is 
stimulated by the phosphate regulating hormone fibroblast growth factor-23 
(FGF23) and suppressed by PTH[14, 17]. As 24,25(OH)2D is the main product of 
25(OH)D catabolism by CYP24A1, the measurement of serum 24,25(OH)2D 
concentration can be useful in identifying patients with loss-of-function mutations 
in CYP24A1. The relative ratio of serum 25(OH)D to 24,25(OH)2D concentration 
may serve as an indicator of vitamin D catabolic status. 
Recent advances in methods for measurement of vitamin D metabolites, 
in particular with assays for measurement 25(OH)D, have led to the development 
of a range of semi- and fully automated assays capable of performing 
measurement of large numbers of samples. Competitive protein binding assays 
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and enzyme immunoassays using chemiluminescent detection-based systems in 
fully automated platforms appeal to hospital laboratories due to their ease of use, 
speed and efficiency[18]. However, immunoassays have variable cross-reactivity 
with other vitamin D metabolites and are unable to distinguish the two major 
forms of vitamin D (D3 and D2). This results in some immunoassays significantly 
underestimated an individual’s true vitamin D status[19]. Liquid chromatography 
tandem mass spectrometry (LC-MS/MS) methods quantify vitamin D metabolites 
based on the compound specific precursor to product ion mass-to-charge (m/z) 
transitions. They are able to distinguish each hydroxylation metabolite and their 
respective D3 and D2 forms. Proficiency testing bodies such as the International 
Vitamin D External Quality Control Scheme (DEQAS) have reported that 
measurement of 25(OH)D by LC-MS/MS methods using traceable calibration 
standards from the National Institute of Standards and Technology (NIST) exhibit 
the lowest inter-laboratory imprecision in comparison with immunoassays[20]. 
LC-MS/MS is now considered to be the reference method for measurement of 
25(OH)D. 
In this study, our aim was to develop a robust and sensitive assay to 
measure 25(OH)D and 24,25(OH)2D simultaneously in human serum samples. 
Our objective was to apply the assay to measure vitamin D metabolites in a large 
cohort of healthy individuals and patients to examine the clinical correlation of 
24,25(OH)2D with 25(OH)D. Our goal was to establish from our cohort of healthy 
individuals: 1) reference intervals for serum 24,25(OH)2D and 
25(OH)D:24,25(OH)2D ratio; 2) to determine the diagnostic accuracy of 
24,25(OH)2D measurement as an indicator for vitamin D status; and 3) to identify 
a 24,25(OH)2D cut-off threshold when vitamin D status is sufficient; i.e. serum 
25(OH)2D concentration ≥50 nmol/L, as defined by the U.S Institute of Medicine 
(IOM) and the UK National Osteoporosis Society (NOS)[21, 22]. Recent 
publications have reported reference intervals of 25(OH)D:24,25(OH)2D ratio on 
smaller cohorts [23-25], or post-menopausal women supplemented with vitamin 
D[26]. In this paper, we established the reference intervals from a large cohort of 
unsupplemented individuals using a statistical approach supported by the 
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
working group[27]. 
2.0 Materials and methods 
2.1 Serum sample collection 
The characteristics of the subjects included in the study are shown in 
Table 1. Serum samples used in the healthy cohort (n=1996) were obtained from 
young British Army recruits during initial training (ClinicalTrials.gov Identifier 
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NCT02416895). The study was approved by the UK Ministry of Defence research 
ethics committee (MODREC). Written informed consent was obtained from all 
study participants. The participants were from Caucasian population and each 
required to complete details in a health questionnaire, including the use of 
medications and supplements. Individuals taking calcium and vitamin D 
supplements were excluded from the study. Samples were collected between 
June 2014 and March 2016.  
Serum from patients (n=294) were collected from residual samples 
following their course of routine care in accordance with generic ethical 
approval[28]. The patient samples collected were routine requests for 25(OH)D 
measurement received by the Department of Laboratory Medicine at the Norfolk 
and Norwich University Hospital between Feburary 2015 to March 2016.  From 
the clinical information available, the cohort contained patients from Caucasian 
population presented with fatigue/wellness-check (42.6%), osteoporosis (23.9%), 
primary hyperparathyroidism (19.9%), liver disease (5.7%), chronic renal failure 
(6.2%) and unknown (1.7%). Use of vitamin D supplements or drugs known to 
affect mineral metabolism were reported in 32% of the patients. All samples were 
anonymised to the researchers at point of access. Blood samples were collected 
into serum gel separator tube (BD Vacutainer) and centrifuged immediately. After 
a 10 minute centrifugation at 3,000 x g, serum layer was aliquoted into a 
separate polystyrene tube and stored at -20C until analysis. 
2.2 Materials, calibration standards and controls 
SRM972 traceable 25(OH)D3 and 25(OH)D2 serum based calibrators 
(Chromsystems, München, Germany) and internal quality controls (IQC) (UTAK 
Laboratories, CA, USA) were analysed in each run. Certified pure standards for 
24,25(OH)2D3, 24,25(OH)2D2 were used for preparation of spiked standards and 
deuterated standards 25(OH)D3-[
2H6] and 24,25(OH)2D3-[
2H3] (IsoSciences, King 
of Prussia, PA, USA) were used as internal standards. Deionised water, 
methanol, acetonitrile and formic acid were LCMS grade, n-heptane and 
isopropanol were analytical grade (Fisher Scientific, Loughborough, UK). 4-
phenyl-1,2,4-triazoline-3,5-dione (PTAD) and methylamine (Sigma-Aldrich, 
Dorset, UK) were used for derivatization and adduct formation. 
2.3 Sample preparation procedure for LC-MS/MS 
Sample preparation and extraction were processed using the Extrahera™ 
automation system (Biotage, Uppsala, Sweden), under positive pressure 
supplied from a nitrogen generator (Peak, Scotland, UK) at flow rate of 30L/min. 
In a 96 position 2mL deep well plate, 100 L of calibration standards, IQC 
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materials or serum samples were diluted with 200 L of pre-treatment solution 
consisting of deuterated internal standards in isopropanol:water 50:50 (v/v). After 
mixing, the samples were loaded onto ISOLUTE® supported liquid extraction 
(SLE+) 400 L plate (Biotage). Elution was carried out by adding two cycles of 
750 L of n-heptane, both cycle of eluents were collected into corresponding 
deep well plate. Positive pressure was applied at each stage to remove residual 
solvent. Samples were then dried under a gentle stream of nitrogen gas heated 
to 45C. Derivatization took place by adding 50 L of 1.1 mmol/L PTAD in 
acetonitrile, into all wells. The plate was vortexed and allowed to incubate for 30 
minutes at room temperature in the dark. 50 L of water was then added and 
mixed to stop the reaction. 20 L of the derivatized extracts was injected into the 
LC-MS/MS. Using this sample preparation procedure, a batch of 96 samples can 
be processed in one hour. 
2.4 Liquid chromatography 
Extracted samples were injected into LC-MS/MS by Waters® 2777 
Sample manager (Waters Corp., Milford, MA, USA) equipped with 3-drawer 
cooler stack regulated at 10˚C. Chromatographic separation was achieved using 
a core-shell C18 50 × 2.1mm, 2.6 µm, reversed-phase (Restek, Bellefonte, PA, 
USA) column heated at 55˚C. An in-line 2µm, 6.35mm × 24mm guard filter was 
used to protect the column. A gradient elution profile was set up using a binary 
UPLC pump (Flux Instruments, Switzerland) to deliver mobile phase at flow rate 
of 0.4 mL/min. At the start of the gradient the mobile phase consisted of 50:50 
(v/v) of (A) water containing 0.2 mM methylamine in 0.1% formic acid and (B) 
methanol containing 0.2 mM methylamine in 0.1% formic acid. The gradient was 
gradually increased to 99% of methanol mobile phase (B) then returned to 
starting gradient at 4 minutes. Solvent divert was employed to divert ion 
suppression regions of the separation to waste in order to minimise 
contamination to the source of the mass spectrometer. 
2.5 Tandem mass spectrophotometry analysis 
 LC-MS/MS analysis of vitamin D metabolites was performed using 
Micromass Quattro Ultima Pt electrospray ionisation (ESI) tandem mass 
spectrometer (Waters Corp., Milford, MA, USA). MassLynx version 4.1 and 
QuanLynx software (Waters Corp., Milford, MA, USA) were used for system 
control, data acquisition, baseline integration and peak quantification. 
Optimisation of MS/MS parameters was accomplished by direct infusion of 
derivatized standards (Fig.1a). Capillary voltage was set at 3.0 kV and RF lenses 
1 and 2 were set at 0.1. Source temperature was maintained at 90˚C. Nitrogen 
was used as both nebuliser gas at flow rate of 30 L/hr and as desolvation gas at 
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flow rate of 850 L/hr at 120˚C. Sample cone voltage and collision energy for all 
vitamin D metabolites were 35kV and 25kV respectively. Argon gas was applied 
to the collision cell during the Collision Induced Dissociation (CID) process. The 
precursor to product ion transitions for each of the compounds were ascertained 
based on the molecular weight of the methylamine adduct of PTAD derived 
products (Fig.1b and 1c). 
2.6 Method validation 
 We followed assay validation guidance from the 2013 U.S Food and Drug 
Administration (FDA)[29] and the 2012 European Medicines Agency (EMA)[30]. 
Human sera based calibration standards for 25(OH)D3 and 25(OH)D2 
(Chromsystems) were used to ensure traceability to SRM972. Where commercial 
calibration material was not available for 24,25(OH)2D3 and 24,25(OH)2D2, 
certified pure standards were spiked gravimetrically into vitamin D depleted 
human serum, representing the same biological matrix as samples. IQC 
materials were incorporated into each batch, the concentrations of IQCs were 
spread across the analytical range; from base level at three times the 
concentration of lower limit of quantification (LLoQ) to top level at the upper 
assay limit[29]. IQC provided the basis of accepting or rejecting the batch, our 
assay acceptance criteria require over half of the IQC samples analysed in each 
batch produce results within 15% from their respective target value, and 20% at 
LLoQ[30]. 
2.7 Linearity 
 Serum standards with known concentrations ranged from 0-180 nmol/L for 
25(OH)D3 and 25(OH)D2, and 0-19.3 nmol/L for 24,25(OH)2D3 and 24,25(OH)2D2 
were analysed at the start and end of every batch. A standard curve was 
generated by plotting the ratio of analyte peak area to internal standard peak on 
the y-axis against the weighted (1/x) concentration of their respective standards 
on the x-axis. The goodness-of-fit of a standard curve is justified by linear 
regression that produced a correlation coefficient (r2) value of >0.980. 
2.8 Accuracy, precision and recovery 
 The accuracy of an analytical method can be influenced by sample 
matrix[31, 32], endogenous components such as phospholipids in biological 
fluids are a major source of ion suppression in LC-MS/MS analysis[33]. Spike 
and recovery experiments were performed at low, medium and high 
concentrations across the analytical range to test the effects of biological matrix 
and sample types (serum and EDTA plasma) on efficiency of sample extraction. 
A multiple reaction monitoring (MRM) transition using the 184 Da product ion of 
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phospholipids was included into the acquisition method to monitor the level of 
phospholipids present in the sample matrix. Imprecision of the assay was 
assessed by ten consecutive measurements of IQC materials within a single run 
(intra-assay) and repeatedly (n = 53) over a three month period (inter-assay). 
Precision is expressed as coefficient of variation (CV), our acceptance criteria 
defined the intra-assay CV limit of <10% and cumulative inter-assay CV limit 
<15%. 
2.9 Lower limit of quantification and detection 
 A precision profile was carried out to determine the lower limit of 
quantification (LLoQ) and detection (LLoD) of the assay. Samples containing 
25(OH)D3, 25(OH)D2, 24,25(OH)2D3 and 24,25(OH)2D2 at concentrations of 0.05, 
0.12, 0.19, 0.41, 0.81 and 1.24 nmol/L were each analysed six times, the CVs of 
each sample were plotted against their respective concentration. The analyte 
peak must produce a signal-to-noise (s/n) ratio of 10:1, the LLoQ was defined as 
the concentration at which the CV  22%. 
2.10 Method comparison 
 Method comparison of 25(OH)D3 was conducted against our published 
LC-MS/MS method[34]. Serum samples (n=630) that were previously analysed 
for 25(OH)D3 and 25(OH)D2 were retested by the current method. Samples from 
the vitamin D external quality assurance scheme (DEQAS)[35] were analysed 
and results compared against the LC/MS method mean. 24,25(OH)2D3 
measurements from samples distributed between April 2015 to January 2016 (n 
= 20) were submitted to the proficiency testing scheme for variability assessment. 
Passing-Bablock regression was used to assess comparability of results between 
methods, a correlation is deemed satisfactory if the linear regression produced a 
correlation coefficient (r2) value of >0.90. 
2.11 Statistical data analysis 
Scatterplots, residual plots, box-whisker graphs and Loess curve were 
constructed and analysed by Statistical Package for the Social Science (SPSS) 
version 22.0.0.1 (IBM, New York, USA). Passing-Bablock regression analysis 
and one-way ANOVA were used to establish inter-quartile range and compare 
variables. Loess curve fitting was employed to explore nonlinear relationships 
between variables and identify inflection points. Statistical significance was 
defined as p <0.05.  Frequency distribution histograms of the data were visually 
examined and checked for transcriptional, pre/post analytical errors before 
exclusion for statistical analysis. Outliers were identified as outside the 2.5% and 
97.5% of the population and removed to establish the Trimmed Mean. 
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2.12 Partitioning for gender 
 The mean and standard deviation of the data were divided according to 
gender. Harris and Boyd’s standard deviate test[36] was used to determine the 
need for gender partition. 
Deviate test: 𝑍 = ?̅?2 − ?̅?1 [(𝜎12 𝑛1⁄ ) +  (𝜎22 𝑛2⁄ )]1/2⁄  
𝑍(𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙) = 3[(𝑛1 + 𝑛2 240⁄ )]1/2 
(?̅?: mean, 𝜎: standard deviation, 𝑛: sample size, 1: male, 2: female) 
Partitioning is required if the statistical  𝑍 ≥ 𝑍(𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙) . In this study, the 
𝑍(𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙) value is 8.65. 
2.13 Establishing the reference intervals and cut-off value for clinically 
significant change 
 For the determination of reference intervals we followed the approach 
supported by the International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) working group[27]. Statistical analysis was performed using 
SPSS Statistical package, based on non-parametric method, which does not 
assume Gaussian distribution. Assessment of the lower and upper reference 
limits were estimated at 2.5th and 97.5th percentiles of the reference distribution. 
Determination of the cut-off value for clinically significant change was estimated 
using the Jacobson and Truax method of analysis[37, 38]. By categorising the 
total 24,25(OH)2D concentrations obtained from our cohort of healthy subjects 
into two subgroups of serum total 25(OH)D concentration 1) less than 50 nmol/L 
(vitamin D deficient/insufficient) or 2) greater than 50 nmol/L (vitamin D sufficient), 
the decision cut-off value was calculated as follows: 
𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 =
(?̅?1 × 𝜎2) + (?̅?2 × 𝜎1)
𝜎2 + 𝜎1
 
(?̅?: mean, 𝜎: standard deviation, 1: vitamin D deficient/insufficient , 2: vitamin D 
sufficient group) 
The diagnostic sensitivity and specificity of the cut-off was assessed by using 
Receiver Operating Characteristics (ROC) curve. In this method, the total 
24,25(OH)2D concentrations obtained from the healthy subjects were grouped 
according total 25(OH)D concentration of 1: greater (true negatives), or 0: less 
than 50 nmol/L (true positives). The ROC curve was generated by plotting 
sensitivity (true positive rate) against 1  specificity (false-positive rate). The 
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accuracy of the test is measured by the area under the ROC curve (AUC), an 
AUC value of >0.9 is classified as a highly accurate test. 
3.0 Results 
 Chromatographic peaks for 24,25(OH)2D3, 24,25(OH)2D2 , 25(OH)D3 and 
25(OH)D2 were eluted at 1.39, 1.42, 1.68 and 1.73 minutes respectively (Fig.1d). 
Total injection-to-injection run time was achieved in 4 minutes. An ion 
suppression test was conducted by post column infusion of an aqueous mixture 
of vitamin D metabolites with a simultaneous injection of an extracted pooled 
serum. Baseline signals were found to be depressed during 0 - 0.8 minutes of the 
chromatographic run and elevated between 2.8 – 3.2 minutes. A switch valve 
was employed to divert parts of the sample where ion suppression and ion 
enhancement occurred to waste. 
3.1 Method validation, recovery efficiency and removal of phospholipids 
 Assay validation is summarised in Table 2. The assay achieved adequate 
linearity (Fig.1e), sensitivity, precision, and demonstrated reproducible recovery 
to satisfy method validation criteria. Injections of aqueous blank after running 
samples of spiked standards containing 1 mol/L of 24,25(OH)2D3, 24,25(OH)2D2 , 
25(OH)D3 and 25(OH)D2 affirmed the absence of carry-over of analytes. Injection 
of a single analyte standard confirmed no cross interference in the other analyte 
transitions. Levels of phospholipids in sample matrix were monitored by the 
acquisition of m/z transitions of the 16 most abundant phospholipid precursor 
ions. However, due to the impracticality of monitoring all 16 ion transitions, a 
single lysophospholipid transition m/z 522>184 that co-eluted with the vitamin D 
metabolites was chosen in sample analysis (Fig.1f). We found complete 
elimination of lysophospholipid peaks in samples extracted using the supported 
liquid extraction method. This resulted in a ten-fold increase in peak signal-to-
noise ratio observed in all analytes. 
3.2 Method comparisons 
 To assess the comparability of the new method, we retested 630 serum 
samples previously analysed for 25(OH)D3/D2 using our existing published LC-
MS/MS method. Passing-Bablock regression analysis (Fig.1g) showed a strong 
correlation with the existing method, the line of best fit generated a slope of 1.04 
(r2 = 0.962, p<0.001). Residual plot (Fig.1h) showed no systematic bias. 
Evaluation of variability in measurements of 24,25(OH)2D3 was performed by 
comparing our results produced from DEQAS samples against mean 
concentrations submitted by other participants. Passing-Bablock Regression 
(Fig.2a) and residual plots (Fig.2b) illustrated the correlation and difference in 
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values measured by our method with other registrants of DEQAS. A significant 
linear association (r2 = 0.926, p<0.001) was found and, the residual plot showed 
no systematic bias or concentration dependent variance between the methods. 
3.3 Partitioning for gender 
 The healthy male and healthy female groups were subjected to the Harris 
and Boyd deviate test. The 𝑍  values determined for total 25(OH)D, total 
24,25(OH)2D, and 25OHD:24,25(OH)2D ratio were 1.61, 4.0 and 5.86, 
respectively. Each calculated 𝑍 value is ≤ 𝑍(𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙) value of 8.65. Therefore, 
partitioning for gender is not required in establishing the reference intervals. 
3.4 Reference intervals in healthy population 
Samples from healthy individuals with plasma intact parathyroid hormone 
(PTH) or adjusted serum calcium concentration (ACa) of greater or less than the 
healthy reference range (PTH: 1.6-6.9 pmol/L, ACa 2.2-2.6 mmol/L) were 
excluded. Based on our exclusion criteria, 1996 samples (1492 male, 504 female, 
age 18-32yrs, mean BMD T-score 1.2±0.1) were included in the statistical study. 
The upper 97.5th and lower 2.5th reference limits for total (sum of D3 + D2) 
25(OH)D, 24,25(OH)2D, and 25OHD:24,25(OH)2D ratio were established 
according to the non-parametric method of analysis (Table 3). No outlier was 
found. The ROC curve (Fig.3) produced an AUC value of 0.943, which classified 
24,25(OH)2D as an excellent test to discriminate individuals with vitamin D 
insufficiency from adequate status.  
3.5 24,25(OH)2D cut-off value for clinically significant change in vitamin D 
status. 
Determination of the cut-off value for clinically significant change using the 
Jacobson and Truax[37, 38] method approach have estimated total 24,25(OH)2D 
of >4.2 nmol/L to be the threshold value for vitamin D replete status, i.e. serum 
total 25(OH)D concentration 50 nmol/L. The decision cut-off has a true positive 
rate (sensitivity) of 88.8%, and false positive rate (specificity) of 86.3%, as 
indicated by the ROC curve (Fig.3). 
3.6 Relationship between serum 25(OH)D, 24,25(OH)2D and 
25(OH)D:24,25(OH)2D ratio among the healthy and patient population 
 In total, 2290 samples collected from healthy volunteers (n = 1996) and 
patients (n = 294) were analysed for serum vitamin D metabolites and included in 
the statistical analysis. 25(OH)D3 was quantified in all samples with a 
concentration range (mean±SD) between 3.1 – 349.8 nmol/L (62±33.2 nmol/L), 
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from which we were able to quantify 24,25(OH)2D3 in 99.8% of samples. 
24,25(OH)2D3 concentrations ranged between 0.2 – 51.1 nmol/L (5.5±3.7 nmol/L). 
25(OH)D2 was present in 12.9% of samples, with a range between 0.1-74.5 
nmol/L (5.4 ±9.5 nmol/L), of which 1.1% contained 24,25(OH)2D2 concentrations 
between 1.3 – 5.0 nmol/L (2.4 ±1.1 nmol/L). Statistical analyses were performed 
on total (sum of D3 + D2) values, the distributions were untrimmed and no outlier 
was removed. A concentration-dependent relationship was observed between 
serum 24,25(OH)2D and 25(OH)D (Fig.4a), linear regression analysis indicated 
[24,25(OH)2D] = 0.1 x  [25(OH)D] -0.65; r
2 value of 0.750. In contrast, the ratio of 
25(OH)D:24,25(OH)2D (Fig.4b) showed an indirect relationship with 25(OH)D; 
Loess fitting showed a downward trend in the ratio of 25(OH)D:24,25(OH)2D as 
serum 25(OH)D concentrations increased. Analysis of variance between the 
subgroups showed 25(OH)D and 24,25(OH)2D concentrations in patients were 
significantly lower than healthy individuals (p<0.001), whereas the relative ratio of 
25(OH)D:24,25(OH)2D was significantly higher in patients (p<0.001). The Box-
whisker plots of total 25(OH)D:24,25(OH)2D ratio against serum total 25(OH)D 
grouped into eight concentration categories with an equal number of cases (Fig.5) 
revealed a highly significant increase (p<0.001) in ratio occurred at total 25(OH)D 
concentration below 50 nmol/L. 
3.7 CYP24A1 mutation on patients with elevated 25(OH)D:24,25(OH)2D ratio. 
Using our established reference intervals, we have identified a sample from the 
patient group with an elevated 25(OH)D:24,25(OH)2D ratio of 32; clinical records 
revealed the patient presented with hypercalcaemia and elevated serum 
1,25(OH)D of 293 pmol/L (reference range 43-144 pmol/L). Retrospective 
genetic analysis confirmed bialleic pathogenic mutations in CYP24A1 (c.823T>C, 
p.W275R and c.1315C>T p.R439C). 
4.0 Discussion 
 We describe a robust LC-MS/MS assay for simultaneous measurement of 
24,25(OH)2D3, 24,25(OH)2D2, 25(OH)D3 and 25(OH)D2. Sample clean up using 
supported liquid extraction (SLE) is highly effective for removal of major proteins 
and phospholipids, which are often the cause of instrument loss of sensitivity and 
downtime. Derivatization with PTAD is essential, vitamin D metabolites have low 
ionisation efficiency and readily dissociate into water loss product ions at low 
collision energy. The advantage of the PTAD derivitization is that it adds proton-
affinitive oxygen and nitrogen molecules (Fig.1c) to the structure of vitamin D, 
thus increasing ionisation potential. Derivatization shifts the compound to a 
higher mass range, where background interference from low molecular weight 
species is relatively low. In our hands, SLE with PTAD derivatization produced 
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peak signal response in the x104-x106 region; increase in an order of magnitude 
compared to our previously published method[34]. Assay sensitivity is paramount 
in order to achieve the detection limit required to measure 24,25(OH)2D; 
particularly in CYP24A1 deficient patients with low total 25(OH)D. Our method 
has demonstrated good recovery, intra/inter assay precision and linearity. 
Accuracy of 24,25(OH)2D3 and 24,25(OH)2D2 can be difficult to assess as there 
is currently no international standard material available. We used certified 
standards spiked into vitamin D depleted human sera in order to maintain matrix 
composition between calibration standards and samples. We evaluated our 
DEQAS 24,25(OH)2D3 returns from the four most recent quarterly cycles and 
compared our values against the mean values from all participants. Our assay 
showed good agreement with other methods; all of our returned values were 
within ±2SD of the mean concentration from other laboratories. We must stress 
that the small number of participants currently in the DEQAS 24,25(OH)2D3 
scheme and the disparity in results between laboratories undermine the reliability 
of the statistics. The availability of a gold reference standard and traceable 
materials would help improve accuracy of measurements and reduce inter-
laboratory variation in future. 
 The strong association between serum concentrations of 25(OH)D and 
24,25(OH)2D demonstrated in this study echo the findings from previous 
reports[23, 25, 26, 39, 40]. The concentrations of 24,25(OH)2D exhibited a 
positive, concentration-dependent relationship, which were on average 10% of 
the concentrations of 25(OH)D. We observed a significant increase in 
25(OH)D:24,25(OH)2D ratio at serum 25(OH)D concentration below 50 nmol/L. 
The decrease in relative production of 24,25(OH)2D may result from down 
regulation of CYP24A1 in response to the decline in circulating 25(OH)D3, in 
order to facilitate catabolism to 1,25(OH)D. The reverse is observed in individuals 
with high concentrations of serum 25(OH)D; where production favours 
24,25(OH)D at the expense of 1,25(OH)2D which may act to prevent  toxicity. 
We have investigated the usefulness of 24,25(OH)2D measurement as a 
surrogate marker of vitamin D status and demonstrated its high diagnostic 
accuracy in our healthy cohort. The 24,25(OH)2D cut-off value of 4.2 nmol/L can 
predict an individual’s vitamin D status with good diagnostic sensitivity and 
specificity; a value below the cut-off indicating insufficiency and the likelihood of 
metabolism favouring 1,25(OH)2D; whereas a value above the cut-off indicates 
sufficient vitamin D status with 25(OH)D catabolism likely to favour 24,25(OH)2D 
production.  
The clinical utility of dual measurements to obtain absolute values as well 
as a ratio of 25(OH)D to 24,25(OH)2D is valuable not only in the assessment of 
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vitamin D catabolic status, but also to provide an assessment of CYP24A1 
activity. Based on our cohort of healthy young adult subjects, we defined the 
normal reference interval for total 25(OH)D:24,25(OH)2D ratio between 7 to 23. In 
comparison with current publications, our upper limit is lower than those 
observed by others[23-25], which may be reflective of the subject population, 
selection criteria, and analytical method employed in our study. The reference 
interval provides an indication of an individual’s vitamin D catabolism with a ratio 
value below 7 indicating elevated activity of 24-hydroxylase. Such individuals 
may be at risk of developing resistance to vitamin D treatment. A ratio above 23 
indicates enzyme under activity and possible genetic abnormalities of CYP24A1. 
We detected one patient in our cohort with an elevated ratio (32) and 
hypercalcaemia who on genetic testing turned out to have a biallelic mutation of 
CYP24A1. Molin et al.[41] reported patients with heterozygous or biallelic 
mutations of CYP24A1 are associated with 25(OH)D:24,25(OH)2D ratios >80; 
whereas patients with a single mutant allele or no CYP24A1 mutation have ratio 
values <25. Moderate elevation of 25(OH)D:24,25(OH)2D ratio may be a result of 
substrate depletion from underlying diseases caused by renal impairment[40], 
bone disorders[42] or pathological conditions associated with an increased 
concentration of FGF23[43], all of which affect calcium and phosphate 
homeostasis resulting in an imbalance state of vitamin D catabolism. Detection of 
an elevated 25(OH)D:24,25(OH)2D ratio, especially in patients with 
nephrocalcinosis or renal stones, may indicate a requirement to restrict or avoid 
vitamin D supplementation in order to prevent hypercalcaemia and further stone 
formation. 
 In conclusion, we have developed a robust LC-MS/MS method for the 
simultaneous measurement of 25(OH)D and its metabolite 24,25(OH)2D. The 
reference intervals of 24,25(OH)2D and 25(OH)D:24,25(OH)2D ratio were 
determined from serum analysis of a large cohort of healthy young adults. We 
found remarkable consistency in the 25(OH)D:24,25(OH)2D ratio across the 
entire range of 25(OH)D concentrations, and observed a significant increase in 
25(OH)D:24,25(OH)2D ratio in individuals with insufficient 25(OH)D. The 
reference intervals we have established for 25(OH)D:24,25(OH)2D ratio can help 
clinician in the investigation of patients presenting with diseases and conditions 
resulted from  loss of CYP24A1 activity, and help optimise supplementation 
therapy based on individual differences in serum vitamin D metabolite 
concentration ratio in order to achieve the best response. 
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Tables and figures 
Table 1. Characteristics of the subjects included in the study. 
Figure 1. (a) Mass spectrometer parameter settings and MRM precursor to 
product ion transitions for 25(OH)D3/D2 and 24,25(OH)2D3/D2. (b) Collision-
induced dissociation spectra of PTAD-derivatized 24,25(OH)2D3 
(M+CH3NH3
+ at m/z 623). The precursor to product ion transition m/z 623>298 
was utilised for MRM. (c) Dienophilic reaction of 24,25(OH)2D3 with PTAD and 
formation of methylamine adduct. (d) Chromatogram from an extracted serum 
sample containing 64.7 nmol/L of 25(OH)D3, 46.1 nmol/L of 25(OH D2, 6.4 
nmol/L of 24,25(OH)2D3 and 4.5 nmol/L of 24,25(OH)2D2. (e)  Typical standard 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
curves constructed by plotting the response of each standard on the y-axis 
against their respective concentrations (nmol/L) on the x-axis. Response of each 
compound were determined by the ratio of the peak area of the standards to the 
peak area of the deuterated internal standards. Regression analysis showed a 
typical correlation coefficient r2 > 0.99. (f) Chromatographic traces showing co-
elution of lysophospholipid transition m/z 522>184 with 25(OH)D3/D2. (g) 
Comparison of 25(OH)D3 of the new method (n=630) showing a strong 
correlation (r2 =0.962) with existing published method. (h) Standardised residual 
plot showing the variability of 25(OH)D3 measurements between new and 
existing method. The dashed lines represents ±SD limits of agreement. 
Table 2. LC-MS/MS assay characteristics. Recovery efficiency was 
determined by spiking known quantities of each compound into vitamin D 
depleted serum and into a base pool of EDTA plasma containing endogenous 
vitamin D metabolites. Each spiked sample was aliquoted and analysed over ten 
separate runs. 
Figure 2. (a) Comparison of 24,25(OH)2D3 returns (n=21) with DEQAS all 
laboratory mean. Solid line in the graph represents the fitted regression line. (b) 
Standardised residual plot showing the variability of 24,25(OH)2D3 measurements. 
The dashed lines represents 95% limits of agreement. All values were within 
±2SD.  
Table 3. Summary of reference intervals and cut-off values for adequate vitamin 
D status. 
Figure 3. Diagnostic performance of 24,25(OH)2D in assessment of vitamin D 
status. Receiver Operating Characteristic (ROC) curve depicts diagnostic 
performance sensitivity and specificity levels. () represents the decision 
threshold for vitamin D replete at 24,25(OH)2D concentration of 4.2 nmol/L 
(sensitivity = 88.8%, specificity = 86.3%). Diagonal line is the line of no 
discrimination. 
Figure 4. The relationship of serum total 25(OH)D with (a) serum total 
24,25(OH)2D, (b) total 25(OH)D:24,25(OH)2D ratio. Sample from a cohort of 
mixed patients and healthy individuals (n = 2290). Solid line in (a) represents 
linear regression line, with 95% confidence intervals (dashed lines). Loess fitted 
curve in (b) depicted in solid line (99% point fit), dashed lines represent the lower 
and upper reference intervals (7-23). 
Figure 5. (a) 25(OH)D:24,25(OH)2D ratio profile of 1996 healthy subjects 
against 25(OH)D bins. Each bin contains equal number of subjects to illustrate 
the significantly elevated ratio found in those with serum 25(OH)D <50 nmol/L. 
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Box and whiskers represent the median, interquartile range and 95% population 
intervals. 
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Highlights 
 
 Our LC-MS/MS method for simultaneous measurement of 25(OH)D and 
24,25(OH)2D was validated against industry standard criteria for method 
validation, results were comparable with external proficiency scheme. 
 The reference intervals of 24,25(OH)2D and 25(OH)D:24,25(OH)2D ratio 
were established a large cohort of healthy individuals and patients 
samples. 
 Serum concentrations of 24,25(OH)2D showed a positive, concentration-
dependent relationship with 25(OH)D. 
 25(OH)D:24,25(OH)2D ratio showed a negative relationship with 25(OH)D3 
that was significantly higher at 25(OH)D concentration <50 nmol/L. 
 Elevated 25(OH)D:24,25(OH)2D ratio may indicate possible genetic 
abnormalities of CYP24A1. 
